List of Excipients in Branded Drug ITOVEBI

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Genentech Inc	ITOVEBI	inavolisib	50242-079	CELLULOSE, MICROCRYSTALLINE	2038-04-26
Genentech Inc	ITOVEBI	inavolisib	50242-079	FERRIC OXIDE RED	2038-04-26
Genentech Inc	ITOVEBI	inavolisib	50242-079	FERRIC OXIDE YELLOW	2038-04-26
Genentech Inc	ITOVEBI	inavolisib	50242-079	LACTOSE MONOHYDRATE	2038-04-26
Genentech Inc	ITOVEBI	inavolisib	50242-079	MAGNESIUM STEARATE	2038-04-26
Genentech Inc	ITOVEBI	inavolisib	50242-079	POLYETHYLENE GLYCOL	2038-04-26
Genentech Inc	ITOVEBI	inavolisib	50242-079	POLYVINYL ALCOHOL	2038-04-26

ITOVEBI Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

ITOVEBI (inavolisib) is a once-daily, immediate-release 9 mg film-coated tablet developed by Genentech, a Roche company. Its current formulation uses conventional solid-oral excipients rather than a controlled-release, lipid-based, amorphous-dispersion, or device-enabled platform. The main commercial opportunity is therefore not a new excipient technology for the originator product. It is supply-chain optimization, generic formulation development, differentiated oral delivery, and excipient-enabled lifecycle management.

The FDA approved ITOVEBI on October 10, 2024, in combination with palbociclib and fulvestrant for adults with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer.[1] The product is administered as one 9 mg tablet once daily, with or without food.[1]

What excipients are used in the ITOVEBI tablet?

The publicly disclosed ITOVEBI formulation is a conventional film-coated tablet. The FDA label identifies the following inactive ingredients:

Formulation component	Publicly identified excipient	Likely function
Tablet core	Lactose monohydrate	Diluent and bulking agent
Tablet core	Microcrystalline cellulose	Diluent, binder, compression aid
Tablet core	Croscarmellose sodium	Superdisintegrant
Tablet core	Magnesium stearate	Lubricant
Tablet core	Colloidal silicon dioxide	Glidant and flow aid
Film coating	Hypromellose	Film-forming polymer
Film coating	Titanium dioxide	Opacifier and pigment
Film coating	Talc	Anti-tacking and coating aid
Film coating	Iron oxide pigment	Colorant

The FDA label does not disclose quantitative excipient percentages, manufacturing process parameters, particle-size specifications, granulation conditions, or coating weight gain.[1] Those details are normally contained in the confidential Chemistry, Manufacturing, and Controls section of the new drug application.

The formulation indicates a standard development objective: reproducible compression, rapid tablet disintegration, acceptable dissolution, and stable film coating. There is no public indication that ITOVEBI requires a pH-modifying system, solubilizing surfactant, enteric protection, modified release, or food-effect mitigation technology.

How does ITOVEBI’s excipient strategy affect generic development?

ITOVEBI presents a comparatively accessible oral-solid formulation target. A generic developer would likely seek to reproduce the reference product’s critical quality attributes rather than duplicate its exact qualitative and quantitative composition.

Important generic targets include:

• 9 mg tablet strength.
• Immediate-release dissolution profile.
• Comparable tablet size, hardness, friability, and disintegration.
• Chemical and physical stability over the proposed shelf life.
• Comparable impurity profile.
• Acceptable bioequivalence under fasting and fed conditions.
• Compatibility with coadministration alongside palbociclib and fulvestrant.

The use of lactose, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and colloidal silicon dioxide reduces dependence on specialized excipients. These materials are widely available from multiple suppliers. A generic manufacturer could use a different binder, disintegrant grade, coating system, or pigment package if the finished product meets regulatory requirements.

Which excipient attributes create technical risk?

The main technical risks are formulation execution rather than excipient scarcity.

Attribute	Potential risk
Lactose grade	Variability in particle size, moisture, and compaction behavior
Microcrystalline cellulose grade	Changes in tablet tensile strength and disintegration
Croscarmellose sodium level	Excess may impair compactability; insufficient level may slow dissolution
Magnesium stearate mixing	Over-lubrication may reduce tablet strength and delay dissolution
Colloidal silicon dioxide	Excess may affect flow, blend uniformity, and compression
Film-coat pigments	Color-match and coating-uniformity requirements
Moisture exposure	Potential impact on tablet hardness, dissolution, and degradation
API particle size	Possible effect on blend uniformity and dissolution

A generic developer is unlikely to face a fundamental formulation barrier based solely on the public excipient list. The more significant development challenge is controlling inavolisib content uniformity at a low 9 mg dose while maintaining process robustness.

What formulation opportunities exist for ITOVEBI?

The originator’s conventional tablet creates several lifecycle and generic opportunities.

Smaller or easier-to-swallow tablets

A smaller tablet could address swallowing difficulty among oncology patients receiving multiple oral medicines. Potential approaches include:

• Higher-density direct compression.
• Roller compaction.
• Co-processed excipients.
• Reduced coating weight.
• Optimized API particle engineering.
• Orally disintegrating or rapidly dispersible dosage forms.

A smaller tablet would need to preserve dose uniformity, mechanical strength, dissolution, stability, and patient acceptability. It would also need to avoid creating a formulation that is difficult to manufacture at commercial scale.

Orally disintegrating tablets

An orally disintegrating tablet could provide a differentiated product for patients with nausea, dysphagia, mucositis, or difficulty swallowing. The opportunity is technically plausible but commercially limited by the current once-daily tablet regimen and the availability of standard oral administration.

Key formulation constraints include:

• Taste masking.
• Rapid wetting and disintegration.
• Low friability.
• Adequate drug loading.
• Moisture protection.
• Packaging in high-barrier blister systems.
• Demonstration that the modified dosage form does not materially alter exposure.

A new dosage form would likely require a regulatory pathway beyond a simple generic ANDA if it changes administration characteristics or clinical use.

Sprinkle or dispersed administration

A capsule or granule-based presentation could allow administration in soft food or liquid. This might benefit patients unable to swallow tablets, but it would create a larger regulatory and stability package. Inavolisib handling, light sensitivity, dose uniformity, and exposure after dispersion would require evaluation.

The current FDA labeling instructs patients to swallow the tablet whole and does not identify an approved crushing, splitting, dissolving, or dispersing procedure.[1] That restriction creates a possible lifecycle opportunity, but it also creates a need for dedicated compatibility, dose-delivery, and stability data.

Modified-release formulations

A controlled-release version has limited apparent commercial rationale. ITOVEBI is already administered once daily, and the public label does not identify a food-dependent dosing restriction that would require release engineering.[1] Modified release could still be relevant if it reduces peak-related toxicity, improves tolerability, or enables a lower dosing frequency. Those benefits would require clinical evidence and would face a higher development burden than a conventional immediate-release product.

Amorphous solid dispersions and lipid systems

The public commercial formulation does not identify an amorphous solid dispersion or lipid-based delivery system. A developer could investigate these systems if inavolisib’s solubility, permeability, or dose-uniformity characteristics create a formulation constraint. Such systems would be more relevant to:

• Reducing tablet mass.
• Improving dissolution at low excipient load.
• Enabling liquid or pediatric presentations.
• Improving robustness across gastrointestinal conditions.

They would also introduce physical stability, recrystallization, scale-up, and bioequivalence risks. There is no public evidence that these technologies are necessary for the approved product.

What commercial opportunities exist for excipient suppliers?

The most immediate opportunity is recurring supply of conventional pharmaceutical-grade excipients for generic and regional products.

High-probability supply opportunities

Excipient suppliers can compete on:

• Direct-compression lactose.
• Low-moisture microcrystalline cellulose.
• High-performance croscarmellose sodium.
• Low-peroxide colloidal silicon dioxide.
• Consistent magnesium stearate.
• Film-coating premixes.
• Pigment systems matched to the ITOVEBI appearance.
• High-barrier blister and bottle packaging.

The value proposition is likely to be manufacturing consistency, regulatory documentation, and dual-source qualification rather than a proprietary excipient platform.

Higher-value differentiated opportunities

More specialized opportunities include:

1. Co-processed excipients that improve low-dose content uniformity.
2. Low-lubrication systems that preserve rapid dissolution.
3. Moisture-control excipients for improved shelf stability.
4. Taste-masking systems for orally disintegrating or dispersed formulations.
5. Ready-to-use film-coating systems that reduce development time.
6. Excipient systems compatible with continuous manufacturing.
7. Pediatric-friendly formulations if the clinical and regulatory strategy expands.

An excipient supplier with a strong oncology portfolio could position an inavolisib platform around low-dose, high-potency active pharmaceutical ingredients. The commercial advantage would come from validated process performance across multiple products, not from ITOVEBI alone.

How does ITOVEBI compare with competing PI3K-pathway products?

ITOVEBI differs from several earlier PI3K-pathway products in both formulation and commercial positioning.

Product	Active ingredient	Key formulation profile	Commercial implication
ITOVEBI	Inavolisib	Conventional 9 mg film-coated tablet; once daily	Low apparent excipient complexity
PIQRAY	Alpelisib	Film-coated tablets in multiple strengths	Broader dose-strength and generic substitution considerations
TRUQAP	Capivasertib	Film-coated tablets; intermittent dosing schedule	More complex regimen may create adherence and packaging opportunities
Aliqopa	Copanlisib	Intravenous formulation	Excipient and manufacturing barriers differ materially from oral products

PIQRAY and TRUQAP provide the closest commercial comparisons because both are oral kinase inhibitors used in advanced breast cancer. ITOVEBI’s once-daily schedule may support adherence, while its 9 mg strength creates a low-dose content-uniformity requirement. PIQRAY’s multiple tablet strengths may create more opportunities for strength-specific excipient optimization, but they also increase manufacturing complexity.

ITOVEBI is used with palbociclib and fulvestrant. That combination creates a potential packaging and adherence opportunity, including co-packaged regimens or coordinated dispensing. A co-pack would face regulatory, contractual, and distribution constraints because the three products may have different sponsors, patent positions, and reimbursement channels.

When does ITOVEBI lose exclusivity?

ITOVEBI’s market protection has several components:

Protection category	Status
FDA approval	October 10, 2024
New chemical entity exclusivity	Expected to run for five years from approval, subject to statutory exceptions
Orphan-drug exclusivity	Not indicated for the approved breast-cancer indication
Pediatric exclusivity	Not established by the approval itself
Patent protection	Depends on issued and listed U.S. patents and their adjusted expiration dates
Regulatory exclusivity outside the U.S.	Varies by jurisdiction

Under the Hatch-Waxman framework, an ANDA containing a Paragraph IV certification can be filed before patent expiration. Commercial launch may still be blocked by patent litigation, a 30-month stay, a court injunction, or a settlement agreement.

The FDA approval letter and labeling establish the regulatory approval date, but they do not by themselves provide a complete patent-expiration analysis.[1] Orange Book patent listings must be reviewed for the current product-specific status, including patent numbers, use codes, and any pediatric or patent-term adjustments.[2]

What Orange Book and Paragraph IV issues affect ITOVEBI?

ITOVEBI is an FDA-approved small-molecule drug, so it is subject to the Hatch-Waxman generic framework rather than the biosimilar pathway.

Potential ANDA certification categories include:

• Paragraph I, if no relevant patent is listed.
• Paragraph II, if a listed patent has expired.
• Paragraph III, if the applicant will wait until patent expiration.
• Paragraph IV, if the applicant alleges that a listed patent is invalid, unenforceable, or not infringed.

The highest-value patent risks would usually involve:

• Inavolisib composition of matter.
• Salt, polymorph, or crystalline forms.
• Pharmaceutical compositions.
• Specific dosage strengths.
• Combination treatment with palbociclib and fulvestrant.
• Treatment of PIK3CA-mutated breast cancer.
• Manufacturing processes.
• Solid-state or particle-size controls.

A generic product using different excipients could avoid a narrow formulation patent, but it would not avoid a composition-of-matter or method-of-use patent. Conversely, a method-of-use patent may be less relevant to a product label that omits the patented indication, subject to induced-infringement and skinny-label analysis.

No biosimilar pathway applies because inavolisib is a chemically synthesized small molecule, not a biologic.

What patent litigation and settlement risks exist?

The principal litigation risk is likely to arise when an ANDA applicant files a Paragraph IV certification against listed inavolisib patents. The relevant sequence would be:

1. The generic applicant sends a Paragraph IV notice.
2. The patent holder may file suit within 45 days.
3. Filing may trigger a statutory 30-month stay of approval.
4. The parties may litigate validity, enforceability, and infringement.
5. The case may end in judgment, license, or delayed-entry settlement.

A formulation-specific patent may be commercially important if it covers the marketed tablet rather than an optional formulation. A generic developer with a non-infringing excipient system may reduce that risk. The strongest barriers would generally be a valid composition-of-matter patent or a broad, enforceable method-of-use patent.

No publicly established settlement date or final Paragraph IV outcome is identified in the FDA approval materials cited here.[1] Orange Book and federal court records control the current status.

What FDA regulatory status applies to ITOVEBI?

ITOVEBI received regular FDA approval for adults with PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer after progression during or after endocrine therapy.[1] The approval is based on the INAVO120 trial, which evaluated inavolisib with palbociclib and fulvestrant against palbociclib and fulvestrant alone.

From an excipient perspective, the FDA pathway creates three commercial routes:

Route	Product concept	Regulatory burden
ANDA	Same active ingredient and dosage form	Lowest, if pharmaceutical equivalence and bioequivalence are established
505(b)(2)	New dosage form, administration method, or formulation	Moderate to high; may rely partly on reference-product data
Full NDA	New clinical use or materially different product	Highest

An excipient change within an equivalent immediate-release tablet may support an ANDA if the product meets the relevant pharmaceutical equivalence and bioequivalence requirements. A new dosage form, administration route, or clinically meaningful release profile is more likely to require a 505(b)(2) application or a new NDA strategy.

What generic launch scenarios exist?

Three launch scenarios are commercially relevant.

Early Paragraph IV launch

A generic company challenges key patents and wins, invalidates them, or obtains a favorable non-infringement judgment. This creates the earliest possible entry, subject to FDA approval and any remaining exclusivity.

Authorized or settlement-based entry

The patent holder licenses a generic or agrees to a defined future entry date. The generic may receive an earlier entry date than the listed patent expiration while preserving the originator’s market position until settlement entry.

Post-exclusivity entry

Generic manufacturers wait for regulatory and patent barriers to expire. In this scenario, standard excipient substitution and manufacturing efficiency become the main competitive levers.

Because ITOVEBI launched in 2024, the first commercial generic window is likely to depend more heavily on the patent estate than on the five-year NCE exclusivity period. The earliest generic filing date and the earliest launch date are separate questions.

How strong is the ITOVEBI formulation estate?

The public excipient profile suggests moderate formulation complexity and potentially limited standalone excipient defensibility. Conventional excipients are generally easy to source and substitute. The commercially stronger protections are more likely to arise from:

• Inavolisib composition of matter.
• Solid-state form.
• Combination therapy.
• PIK3CA-mutated patient selection.
• Specific treatment sequencing.
• Manufacturing controls not visible in the public label.

A formulation patent covering only a conventional lactose-cellulose-disintegrant tablet would face design-around pressure. A patent covering a specific inavolisib solid form, impurity profile, dissolution range, or manufacturing process could create a stronger practical barrier.

Key Takeaways

• ITOVEBI is a conventional once-daily 9 mg film-coated tablet.
• Publicly identified excipients include lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, hypromellose, titanium dioxide, talc, and iron oxide pigment.
• The formulation does not publicly indicate controlled release, lipid delivery, enteric protection, or a specialized solubilization platform.
• The strongest excipient opportunities are supply reliability, low-dose content uniformity, coating systems, moisture protection, and differentiated swallowability.
• Generic developers can likely design around individual excipients, subject to bioequivalence and quality requirements.
• The main intellectual-property barriers are more likely to involve composition of matter, solid-state forms, manufacturing, and method of use than ordinary tablet excipients.
• ITOVEBI is a small molecule and is not subject to the biosimilar pathway.
• Current Orange Book listings, patent-term adjustments, Paragraph IV notices, litigation, and settlement terms determine the practical generic-entry timeline.

FAQs About ITOVEBI Excipient and Generic Strategy

Can ITOVEBI tablets be crushed or split?

The FDA labeling directs patients to swallow ITOVEBI tablets whole. It does not establish an approved crushing, splitting, or dispersing procedure.[1]

Is ITOVEBI a modified-release formulation?

No public FDA labeling indicates modified release. ITOVEBI is supplied as a once-daily film-coated tablet.[1]

Can a generic ITOVEBI use different excipients?

Yes. A generic applicant generally does not need to duplicate every inactive ingredient, but the product must meet applicable pharmaceutical equivalence, bioequivalence, quality, stability, and labeling requirements.

Is inavolisib eligible for biosimilar competition?

No. Inavolisib is a chemically synthesized small molecule. Competition would generally proceed through the generic-drug framework, including ANDA filing and possible Paragraph IV litigation.

Which excipient technology has the greatest commercial potential for ITOVEBI?

Low-dose content-uniformity systems, smaller tablets, orally disintegrating presentations, moisture-protective packaging, and ready-to-use coating systems offer the clearest opportunities. Their commercial value depends on demonstrating a meaningful manufacturing, adherence, or patient-use advantage over the existing immediate-release tablet.

References

1. U.S. Food and Drug Administration. (2024). ITOVEBI (inavolisib) prescribing information. Genentech, Inc.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. Roche. (2025). Annual report 2024. Roche Holding Ltd.

4. U.S. Food and Drug Administration. (1984). Drug Price Competition and Patent Term Restoration Act of 1984. 21 U.S.C. §§ 355, 355a, 355(j).